|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additionally, the JAK2/STAT3 signalling pathway, which is abnormally active in CML, was inhibited by MBD2 deletion, and MBD2 deletion could up-regulate the expression of SHP1.
|
29565710 |
2018 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Considerable effort is being made to understand the role of JAK2(V617F) at the MPN initiation and to clarify the pathogenesis and apoptosis resistance in CML, PV, ET and PMF patients.
|
27282563 |
2016 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.
|
16001431 |
2005 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Herein, the authors present three cases of CML diagnosed within five years of treatment initiation for Hodgkin's Lymphoma (HL); one of the three patients had CML with atypical variant carrying a rare mutation with BCR-JAK2 fusion.
|
31366526 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
In myeloid diseases we have seen dramatic improvements in the overall survival and quality of life for patients with chronic myeloid leukaemia treated with ABL and Src/ABL kinase inhibitors and we are poised to discover whether JAK2 inhibitors may offer similar benefit in myeloproliferative diseases.
|
20041451 |
2010 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Inhibition of JAK-2 overcomes GM-CSF-induced IM and NI progenitor cell resistance, providing a rationale for the application of JAK-2 inhibitors to eradicate residual disease in CML.
|
17090651 |
2007 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish.
|
22733019 |
2012 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Abnormalities of tyrosine kinase proteins are well recognised in myeloid malignancies, mutation in the cytoplasmic tyrosine kinase JAK2 (V617F) is key in the pathogenesis of myeloproliferative neoplasms, and translocations involving ABL key in the development of chronic myeloid leukaemia.
|
21722956 |
2011 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
JAK2 mutation was also detected in 3 (19%) of 16 patients with Philadelphia-chromosome (Ph)-negative chronic myelogenous leukemia (CML), 2 (18%) of 11 patients with megakaryocytic AML, 7 (13%) of 52 patients with chronic myelomonocytic leukemia, and 1 (1%) of 68 patients with myelodysplastic syndromes.
|
16037387 |
2005 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We studied samples from 1088 persons with myeloproliferative neoplasms (MPNs) including 421 JAK2(V617F) negative subjects with ET, PMF, polycythemia vera (PV), chronic myeloid leukemia (CML) and hyper-eosinophilic syndrome (HES).
|
25860380 |
2015 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However it is not so easy, because iPSCs from hematological malignancies have been established only from myeloproliferative neoplasms including chronic myelogenous leukemia (CML) and JAK2-V617F mutation-positive polycythemia vera (PV). iPSC technology has great potential to promote oncology research based on patient samples.
|
23807288 |
2013 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
LHGDN |
Hematopoietic perturbation in zebrafish expressing a tel-jak2a fusion.
|
15676212 |
2005 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
LCN-2 mRNA showed a near 50-fold increase in expression, accompanied by down-regulation of SLC22A17, coinciding with increase in BCR-ABL transcripts, loss of JAK2-V617F and change of clinical phenotype from polycythaemia vera to chronic myeloid leukaemia.
|
21950422 |
2012 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Key genetic aberrations include the BCR-ABL1 gene rearrangement in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and JAK2/MPL/CALR aberrations in Philadelphia chromosome-negative MPNs.
|
29951914 |
2018 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
LightCycler melting curve analysis was applied to detect risk alleles of TERT rs2736100_C and Janus kinase 2 (JAK2) rs12343867_C tagging 46/1 haplotype in 584 BCR-ABL1-negative MPN, 308 acute, and 86 chronic myeloid leukemia (AML and CML) patients and 400 healthy individuals.
|
26487696 |
2016 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we used mice with a conditional null mutation in the Stat5a/b gene locus to determine the requirement for STAT5 in MPNs induced by BCR-ABL1 and JAK2(V617F) in retroviral transplantation models of CML and PV.
|
22234689 |
2012 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results identify Jak2 as a potentially important therapeutic target for CML.
|
16818614 |
2006 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
The patient was diagnosed with CML and <i>JAK2 V617F</i> mutation.
|
31123683 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Simultaneously targeting BCR-ABL and JAK2 activities in CML stem/progenitor cells may improve outcomes in patients destined to develop IM resistance.
|
23446755 |
2013 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.
|
20809224 |
2010 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia.
|
28602946 |
2017 |
|
Myeloid Leukemia, Chronic
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We found plasma levels of total JAK2 mRNA to be higher in patients with non-CML MPD (n=175) than in CML patients (n=45) and normal controls (n=58) (each P<0.001).
|
19254349 |
2010 |
|
Myeloid Leukemia, Chronic
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Missense mutations of A300V, V402M, and R415H in LNK were found in 8 patients including ET (4 cases, all combined with JAK2-V617F mutation), PV (2 cases, one combined with JAK2-V617F mutation), PMF (one case, combined with JAK2-V617F mutation) and CML (one case, combined with BCR/ABL1 fusion gene).
|
27111338 |
2016 |
|
Myeloid Leukemia, Chronic
|
0.500 |
Biomarker
|
disease |
BEFREE |
We recently demonstrated that the AHI-1 oncogene physically interacts with BCR-ABL and JAK2 and mediates cellular resistance to TKI in CML stem/progenitor cells.
|
22623184 |
2012 |